Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
69.93
-2.84 (-3.90%)
At close: Jan 23, 2026, 4:00 PM EST
70.00
+0.07 (0.10%)
After-hours: Jan 23, 2026, 7:45 PM EST
Kymera Therapeutics Market Cap
Kymera Therapeutics has a market cap or net worth of $5.59 billion as of January 23, 2026. Its market cap has increased by 111.09% in one year.
Market Cap
5.59B
Enterprise Value
4.70B
1-Year Change
111.09%
Ranking
Category
Stock Price
$69.93
Market Cap Chart
Since the IPO on August 21, 2020, Kymera Therapeutics's market cap has increased from $834.48M to $5.59B, an increase of 570.40%. That is a compound annual growth rate of 41.99%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 23, 2026 | 5.59B | -10.13% |
| Dec 31, 2025 | 6.22B | 138.91% |
| Dec 31, 2024 | 2.61B | 84.43% |
| Dec 29, 2023 | 1.41B | 3.16% |
| Dec 30, 2022 | 1.37B | -57.98% |
| Dec 31, 2021 | 3.26B | 18.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Aug 21, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Vaxcyte | 6.22B |
| Cogent Biosciences | 6.07B |
| Belite Bio | 6.00B |
| PTC Therapeutics | 5.87B |
| Crinetics Pharmaceuticals | 5.71B |
| Apogee Therapeutics | 5.54B |
| Immunovant | 5.30B |
| Protagonist Therapeutics | 5.22B |